In order to achieve more ethical global health outcomes, health policies must be driven by health priorities and should take into account broader health policy requirements, including the needs of specific national health systems. It is thus important to recognize that the division of interests in key policy areas are not necessarily between the priorities of rich and poor countries, but between (1) pharmaceutical industry interests and health policy interests, and (2) national industrial and trade policy interests and public health policies. I argue that these issues are not solely the concern of developing countries because the diminishing national policy space for health in pharmaceutical policies presents a challenge to all governments, including rich ones.
To read or purchase the full text of this article, click here.
More in this issue
Winter 2010 (24.4) • Feature
The Politics of Carbon Leakage and the Fairness of Border Measures
It is possible to design fair border measures that address carbon leakage, are consistent with the leadership responsibilities of developed countries, do not penalize developing ...
Winter 2010 (24.4) • Response
The Responsibility to Protect: Growing Pains or Early Promise?
The ability of RtoP to deliver has been mixed, but it is a bit early in RtoP's young life to judge what it will be ...
Winter 2010 (24.4) • Review
Women and States: Norms and Hierarchies in International Society by Ann E. Towns
This new work by Ann Towns is an intelligent and timely addition to interdisciplinary scholarship that is interested in the relationships between the status of ...